reteplase


Also found in: Dictionary, Thesaurus, Legal, Financial, Encyclopedia, Wikipedia.
Related to reteplase: Tenecteplase

reteplase

 [ret´ĕ-plās]
a recombinant form of tissue plasminogen activator; used intravenously as a thrombolytic agent in treatment of myocardial infarction.

reteplase

(rĕ-tĕ'plāz),
A fibrinolytic agent that works by stimulating production of plasmin.
See also: plasmin.

reteplase

/ret·e·plase/ (ret´ĕ-plās) a recombinant form of tissue plasminogen activator; used as a thrombolytic agent in the treatment of myocardial infarction.

reteplase

[ret′ĕ-plās]
a recombinant form of tissue plasminogen activator used intravenously as a thrombolytic agent in treatment of myocardial infarction.

PLAT

A gene on chromosome 8p12 that encodes tissue plasminogen activator, which converts inactive plasminogen to plasmin by hydrolysing a single Arg-Val bond in plasminogen, thereby playing a key role in tissue remodelling, degradation, cell migration and other cellular events. PLAT directly facilitates neuronal migration.

reteplase

Retavase Cardiology A recombinant mutant of alteplase–tPA used to treat acute MI. See Acute myocardial infarction, GUSTO V.

reteplase

A drug that dissolves blood clots. A fibrinolytic drug used in the early stages of a heart attack to try to restore patency to a coronary artery branch that has been blocked by a blood clot. A brand name is Rapilysin.
References in periodicals archive ?
Reteplase is a recombinant non-glycosylated form of human tPA produced in Escherichia coli (E.
In this project, the Q-sepharose Fast Flow was used for separation and purification of reteplase.
Efficacy and adverse effects of reteplase were examined in what is known as the Rapid and Gusto studies (Smalling et al.
Reteplase was chosen as an alternative to urokinase due to its successful use in thrombolysis of arteriovenous grafts performed by the interventional radiologist to whom the dialysis center referred (Gibbens, DePalma, Albanese, Castner, & Troilo, 2000).
Reteplase, which also has a high molecular weight, is used to treat acute MI and is not teratogenic in animals, but in rats and rabbits was an abortifacient.
Of the three trials, perhaps the most prominent was the GUSTO (Global Use of strategies to Open Occluded Arteries) V study which involved 16,588 patients and compared heparin plus a full, bolus dose of the thrombolytic reteplase with a half-dose of reteplase plus abciximab plus heparin.
Summarizing the Thrombolytic Trial Results Trial Drugs GUSTO V Full-dose reteplase plus 16,588 unfractionated heparin OR patients Half-dose reteplase plus abciximab plus unfractionated heparin HERO-2 Streptokinase plus 17,073 unfractionated heparin OR patients Streptokinase plus bivalirudin ASSENT-3 Full-dose tenecteplase plus 6,095 unfractionated heparin OR patients Full-dose tenecteplase plus enoxaparin OR Half-dose tenecteplase plus half-dose abciximab plus unfractionated heparin Trial Outcomes GUSTO V Adding abciximab cut the 16,588 repeat MI rate.
Bolus thrombolytic agents like reteplase are available and much better suited than tissue plasminogen activator for use in the prehospital arena.
The 16,600 acute MI patients in the trial are being randomly assigned to conventional full-dose reteplase or to half-dose reteplase plus full-dose therapy with abciximab.
These findings about the combination of reteplase and abciximab may offer an important new option in the treatment of heart attack," said Eric J.